How to Look Up When Any Drug Patent Expires
Published April 6, 2026
Knowing when a drug patent expires is critical for patients, investors, healthcare providers, and generic manufacturers. It determines when cheaper alternatives become available, when companies face revenue cliffs, and when biosimilar competition begins. Here are four methods to look up any drug patent expiration, from free public tools to professional databases.
4 Ways to Check Drug Patent Expiration Dates
1. PatentCliff.org (Free)
Our own database provides the fastest way to look up drug patent expirations. Search by drug name, brand name, or company to see patent expiration dates, estimated revenue at risk, and competitive landscape analysis. Every drug page includes a timeline visualization and links to the underlying USPTO and FDA data.
- How to use: Go to PatentCliff.org/search and type any drug or company name
- Best for: Quick lookups, revenue impact analysis, understanding the competitive landscape
- Updates: Weekly, from USPTO and FDA data feeds
2. FDA Orange Book (Free, Official)
The FDA Orange Book is the official U.S. government database of approved drug products and their patent information. It is maintained by the FDA and updated monthly.
- How to use: Visit electronic.orangebook.fda.gov, search by active ingredient or proprietary name. Each listing shows patent numbers, expiration dates, and exclusivity codes.
- Best for: Official patent and exclusivity data for FDA-approved small-molecule drugs
- Limitation: Does not include biologics (those are in the separate FDA Purple Book)
3. USPTO PatentsView (Free, Research-Grade)
The USPTO PatentsView platform provides direct access to raw U.S. patent data going back to 1976. It is built for researchers and analysts who need detailed patent claims, citation networks, and inventor information.
- How to use: Search by patent number, assignee (company), or CPC classification code. Filter by grant date, expiration date, or technology area.
- Best for: Deep patent analysis, citation research, academic studies, patent landscape mapping
- Limitation: Raw patent data without drug-specific context — you need to know the patent numbers to look up
4. DrugPatentWatch (Premium, Subscription)
DrugPatentWatch is a commercial database used by pharmaceutical companies, law firms, and investors. It maps FDA-approved drugs to their specific patents and provides expiration forecasts, litigation tracking, and ANDA filing alerts.
- How to use: Subscribe at drugpatentwatch.com, search by drug or company name
- Best for: Industry professionals who need litigation tracking, regulatory filing alerts, and comprehensive patent-to-drug mapping
- Limitation: Paid subscription required (pricing starts at several hundred dollars per month)
Comparison: Which Source Should You Use?
| Source | Cost | Data Scope | Ease of Use | Best For |
|---|---|---|---|---|
| PatentCliff.org | Free | Drug patents + revenue data | Very easy | Patients, investors, quick lookups |
| FDA Orange Book | Free | Official patent + exclusivity | Moderate | Regulatory professionals, pharmacists |
| USPTO PatentsView | Free | All U.S. patents (not drug-specific) | Advanced | Researchers, patent analysts |
| DrugPatentWatch | $$$ / month | Drug patents + litigation + filings | Easy | Pharma companies, IP lawyers |
Understanding Patent vs. Exclusivity
One of the most common sources of confusion is the difference between patent protection and regulatory exclusivity. They are two separate legal mechanisms that can overlap or exist independently:
- Patent protection is granted by the USPTO and lasts 20 years from the filing date. It gives the patent holder the right to exclude others from making, using, or selling the patented invention. A drug may have multiple patents covering different aspects (compound, formulation, method of use, delivery device).
- Regulatory exclusivity is granted by the FDA and prevents approval of generic or biosimilar applications for a set period: 5 years for new chemical entities, 3 years for new clinical investigations, 7 years for orphan drugs, and 12 years for biologics. These run from the date of FDA approval, not from patent filing.
A generic manufacturer cannot launch until both the relevant patents have expired (or been successfully challenged) and all applicable exclusivity periods have ended. This is why the "effective" date of generic entry can differ from the patent expiration date listed in databases.
Why One Drug Has Many Patents
Modern pharmaceutical patent strategy involves filing dozens or even hundreds of patents around a single product. Each patent covers a different aspect of the drug:
- Compound patent: The active ingredient itself. This is the foundational patent and typically expires first.
- Formulation patents: Specific tablet designs, coatings, extended-release mechanisms, or combination products.
- Method-of-use patents: Each approved indication (disease the drug treats) may have its own patent.
- Manufacturing process patents: Specific methods of synthesizing or producing the drug.
- Delivery device patents: Auto-injectors, inhalers, or other devices used to administer the drug.
Humira, the best-selling drug in history, was protected by over 130 patents — a strategy known as a "patent thicket." This delayed biosimilar entry in the U.S. by five years beyond what European regulators allowed. Understanding which patents are most significant (and when they expire) requires looking at the full patent landscape, not just a single date.
Frequently Asked Questions
Is the FDA Orange Book free?
Yes. The FDA Orange Book is completely free to search at electronic.orangebook.fda.gov. It lists all approved drug products with their associated patents, patent expiration dates, and regulatory exclusivity periods. The database is updated monthly. However, the Orange Book only covers drugs approved through New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) — it does not include biologics, which are covered separately under the Purple Book.
Why does one drug have multiple patent expiration dates?
A single drug can be protected by many different patents, each covering a different aspect: the active compound itself, specific formulations (tablets, extended-release), methods of use (treating specific conditions), manufacturing processes, and delivery devices. Each patent has its own expiration date. The last patent to expire determines when full generic competition can begin. Humira, for example, was protected by over 130 patents with expiration dates spanning more than a decade.
What is the difference between patent expiry and exclusivity?
Patent expiry is when the USPTO patent term ends (typically 20 years from filing). Exclusivity is a separate protection granted by the FDA that prevents generic approvals for a defined period — 5 years for new chemical entities, 3 years for new clinical studies, 7 years for orphan drugs, and 6 months for pediatric studies. A drug may have expired patents but still hold FDA exclusivity, or vice versa. Generic manufacturers cannot enter the market until both patent protection and regulatory exclusivity have ended.
Can I find out when my medication will have a generic?
Yes. Search for your medication on PatentCliff.org or the FDA Orange Book to find its patent expiration dates. However, patent expiration does not guarantee immediate generic availability. Generic manufacturers must still file and receive FDA approval, which can take 1-3 years after patent expiration. For biologics, the process is even longer — biosimilar development typically takes 5-8 years. Check our drug pages for estimated timelines on when generics are expected to launch.
About This Data
Patent data from USPTO PatentsView API. Drug approval and exclusivity data from FDA Orange Book. See our methodology.